ArticleTherapeutic advances in respiratory disease
A clinical predictive model for the long-term survival of progressive fibrosis interstitial lung disease patients.
Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn patients with chronic fibrosing interstitial lung disease (ILD), some may develop a progressive fibrosing (PF) phenotype, which presents as rapid progression and often results in poor clinical outcomes.
objectiveThe objective of this study was to construct and test a model to identify independent predictors of mortality in PF-ILD and to trace the lung function trajectory of patients with PF-ILD.
designThis multicenter retrospective cohort study enrolled patients with PF-ILD from two distinct centers with 8-year follow-up to develop and validate a prognostic nomogram based on clinical factors and assess longitudinal lung function trajectories.
methodsWe enrolled patients diagnosed with PF-ILD from China-Japan Friendship Hospital (training cohort) and Jiulongpo Hospital of Traditional Chinese Medicine (validation cohort). Survival status was recorded during the 8-year follow-up period. Clinical demographics, laboratory data, pulmonary function test (PFT) results, and high-resolution computed tomography results were collected for analysis. A training cohort of patients with PF-ILD was used to identify predictors of mortality, which were then validated in an external cohort. A nomogram was established based on multivariate factors. The predictive performance of the model was evaluated using receiver operating characteristic curves and calibration curves. Survival estimates were performed using the Kaplan-Meier method and compared using the log-rank test. The PFT trajectory was estimated using a linear mixed model.
resultsA total of 1419 patients with PF-ILD from China-Japan Friendship Hospital (training cohort) and 282 patients with PF-ILD from Jiulongpo Hospital of Traditional Chinese Medicine (validation cohort) were enrolled. During the 8-year follow-up, 150 (10.57%) patients received lung transplantation, while 43.55% (
conclusionA predictive model incorporating multiple factors effectively predicted 8-year survival in patients with PF-ILD. In addition to these baseline predictors, AEs and progressive declines in FVC and DLCO were strongly associated with poor prognosis and may serve as valuable longitudinal biomarkers for ongoing risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.